Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 11/20 | 0.71 |
| ▸ | CDK2 | P24941 | 8/20 | 0.49 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.49 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.49 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.46 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.44 |
| ▸ | CDK1 | P06493 | 2/20 | 0.43 |
| ▸ | CDK7 | P50613 | 1/20 | 0.43 |
| ▸ | CCNH | P51946 | 1/20 | 0.43 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.43 |
| ▸ | CDK9 | P50750 | 1/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12953836 | 0.91 | GSK3B (0.70) | GSK3BCDK2CCNA2CCNA1CHEK1 | |
| SCHEMBL12954279 | 0.89 | GSK3B (0.71) | GSK3BCDK2CCNA2CCNA1CHEK1 | |
| SCHEMBL14418527 | 0.86 | GSK3B (0.57) | GSK3BCDK2CCNA2CCNA1CCNE1 | |
| SCHEMBL12952914 | 0.83 | GSK3B (1.00) | GSK3BCDK2CCNE1 | |
| SCHEMBL15579638 | 0.82 | GSK3B (0.52) | GSK3BCDK2CCNA2CCNA1CCNE1 | |
| SCHEMBL12953842 | 0.82 | GSK3B (0.54) | GSK3BCDK2CCNA2CCNA1CCNE1 | |
| SCHEMBL13304843 | 0.82 | GSK3B (0.53) | GSK3BCDK2CCNA2CCNA1CCNE1 | |
| SCHEMBL12952999 | 0.80 | GSK3B (0.68) | GSK3BCDK2CCNA2CCNA1CHEK1 | |
| SCHEMBL13116805 | 0.80 | GSK3B (0.70) | GSK3BCDK2CCNA2CCNA1CHEK1 | |
| SCHEMBL12953472 | 0.80 | GSK3B (0.70) | GSK3BCDK2CCNA2CCNA1CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1537116-B1 | PYRAZOLOPYRIMIDINES SUITABLE FOR THE TREATMENT OF CANCER DISEASES | SCHERING CORP (US) | 2010-06-02 | — | — | EP | disclosed |
| US-7161003-B1 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2007-01-09 | — | — | US | disclosed |